James B. Leverenz

42.0k total citations · 5 hit papers
253 papers, 14.7k citations indexed

About

James B. Leverenz is a scholar working on Physiology, Neurology and Psychiatry and Mental health. According to data from OpenAlex, James B. Leverenz has authored 253 papers receiving a total of 14.7k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Physiology, 88 papers in Neurology and 86 papers in Psychiatry and Mental health. Recurrent topics in James B. Leverenz's work include Alzheimer's disease research and treatments (99 papers), Dementia and Cognitive Impairment Research (80 papers) and Parkinson's Disease Mechanisms and Treatments (72 papers). James B. Leverenz is often cited by papers focused on Alzheimer's disease research and treatments (99 papers), Dementia and Cognitive Impairment Research (80 papers) and Parkinson's Disease Mechanisms and Treatments (72 papers). James B. Leverenz collaborates with scholars based in United States, United Kingdom and Japan. James B. Leverenz's co-authors include Thomas J. Montine, Elaine R. Peskind, Murray A. Raskind, Cyrus P. Zabetian, Pamela J. McMillan, Debby W. Tsuang, Joseph F. Quinn, Lynn M. Bekris, Gerard D. Schellenberg and Suzanne Craft and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Neuroscience.

In The Last Decade

James B. Leverenz

246 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

2009 698 citations James B. Leverenz et al. profile →
TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models

2015 525 citations Lynn M. Bekris, James B. Leverenz et al. profile →
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

2010 496 citations Min Shi, Kathryn A. Chung et al. Brain profile →
Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings

2016 318 citations James B. Leverenz et al. profile →
A Systematic Review of Dementia-related Stigma Research: Can We Move the Stigma Dial?

2017 214 citations James B. Leverenz, Alan J. Lerner et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James B. Leverenz United States	69	6.2k	6.1k	3.3k	3.0k	2.9k	253	14.7k
Lucilla Parnetti Italy	61	5.4k 0.9×	5.1k 0.8×	2.7k 0.8×	2.4k 0.8×	3.5k 1.2×	350	14.0k
Eileen H. Bigio United States	47	6.7k 1.1×	4.6k 0.8×	3.5k 1.1×	2.5k 0.9×	3.1k 1.1×	144	12.6k
Irina Alafuzoff Sweden	61	6.9k 1.1×	3.8k 0.6×	4.4k 1.3×	2.6k 0.9×	2.8k 1.0×	205	14.2k
Lawrence S. Honig United States	55	4.6k 0.7×	4.9k 0.8×	3.0k 0.9×	1.5k 0.5×	2.9k 1.0×	182	13.3k
Nigel J. Cairns United States	58	8.5k 1.4×	6.8k 1.1×	5.4k 1.7×	3.4k 1.2×	4.1k 1.4×	181	17.6k
Ulf Andréasson Sweden	57	7.7k 1.2×	3.4k 0.6×	3.9k 1.2×	2.5k 0.8×	4.9k 1.7×	178	13.7k
Marcel M. Verbeek Netherlands	65	5.1k 0.8×	4.4k 0.7×	4.1k 1.3×	2.2k 0.7×	2.2k 0.8×	294	12.9k
Sharon X. Xie United States	68	4.9k 0.8×	5.6k 0.9×	1.9k 0.6×	1.9k 0.6×	3.9k 1.3×	223	15.1k
Johannes Attems United Kingdom	57	5.2k 0.8×	3.8k 0.6×	2.3k 0.7×	2.9k 1.0×	2.6k 0.9×	190	11.0k
Neill R. Graff‐Radford United States	70	7.2k 1.2×	6.3k 1.0×	2.7k 0.8×	2.8k 0.9×	5.8k 2.0×	275	17.2k

Countries citing papers authored by James B. Leverenz

Since Specialization

Citations

This map shows the geographic impact of James B. Leverenz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James B. Leverenz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James B. Leverenz more than expected).

Fields of papers citing papers by James B. Leverenz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James B. Leverenz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James B. Leverenz. The network helps show where James B. Leverenz may publish in the future.

Co-authorship network of co-authors of James B. Leverenz

This figure shows the co-authorship network connecting the top 25 collaborators of James B. Leverenz. A scholar is included among the top collaborators of James B. Leverenz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James B. Leverenz. James B. Leverenz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Zhengshi, Xiaowei Zhuang, Katherine Koenig, et al.. (2024). Pattern separation involves regions beyond the hippocampus in non-demented elderly individuals: A 7T object lure task fMRI study. Imaging Neuroscience. 2. 1–15.

Appleby, Brian S., Charles J. Duffy, James B. Leverenz, et al.. (2023). Primary etiology and associated medical conditions in Mild Cognitive Impairment Subtypes in the NACC Database. Alzheimer s & Dementia. 19(S18). 1 indexed citations

Rao, Stephen M., Rachel Galioto, James B. Leverenz, et al.. (2023). Cleveland Clinic Cognitive Battery (C3B): Normative, Reliability, and Validation Studies of a Self-Administered Computerized Tool for Screening Cognitive Dysfunction in Primary Care. Journal of Alzheimer s Disease. 92(3). 1051–1066. 8 indexed citations

Pillai, Jagan A., James Bena, Lynn M. Bekris, et al.. (2023). Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease. Alzheimer s Research & Therapy. 15(1). 54–54. 42 indexed citations

Zhou, Yadi, Jiansong Fang, Lynn M. Bekris, et al.. (2021). AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery. Alzheimer s Research & Therapy. 13(1). 56 indexed citations

Pillai, Jagan A., James Bena, Aaron Bonner‐Jackson, & James B. Leverenz. (2021). Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer’s and Lewy body neuropathology. Alzheimer s Research & Therapy. 13(1). 31–31. 12 indexed citations

Pillai, Jagan A., James Bena, Lynn M. Bekris, et al.. (2019). Key inflammatory pathway activations in the MCI stage of Alzheimer’s disease. Annals of Clinical and Translational Neurology. 6(7). 1248–1262. 32 indexed citations

Kim, Hojoong M., James B. Leverenz, Daniel Burdick, et al.. (2018). Diagnostic Validation for Participants in the Washington State Parkinson Disease Registry. Parkinson s Disease. 2018. 1–6. 18 indexed citations

Korvatska, Olena, Nicholas S. Strand, Jason D. Berndt, et al.. (2013). Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Human Molecular Genetics. 22(16). 3259–3268. 101 indexed citations

10.

Peterson, Amie, Charles Murchison, Cyrus P. Zabetian, et al.. (2013). Memory, Mood, and Vitamin D in Persons with Parkinson's Disease. Journal of Parkinson s Disease. 3(4). 547–555. 68 indexed citations

11.

Lin, Xiangmin, Travis J. Cook, Cyrus P. Zabetian, et al.. (2012). DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Scientific Reports. 2(1). 954–954. 85 indexed citations

12.

Wang, Yu, Aneeka M. Hancock, Joshua M. Bradner, et al.. (2011). Complement 3 and Factor H in Human Cerebrospinal Fluid in Parkinson's Disease, Alzheimer's Disease, and Multiple-System Atrophy. American Journal Of Pathology. 178(4). 1509–1516. 96 indexed citations

13.

Cimino, Patrick J., Izabela Sokal, James B. Leverenz, Yoshinori Fukui, & Thomas J. Montine. (2009). DOCK2 Is a Microglial Specific Regulator of Central Nervous System Innate Immunity Found in Normal and Alzheimer’s Disease Brain. American Journal Of Pathology. 175(4). 1622–1630. 38 indexed citations

14.

Lane, Roger, Yunsheng He, Christopher M. Morris, et al.. (2008). BuChE‐K and APOE ϵ4 allele frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement Disorders. 24(3). 392–400. 34 indexed citations

15.

Sokal, Izabela, Joseph F. Quinn, James B. Leverenz, et al.. (2007). CSF tau/Aβ ₄₂ ratio for increased risk of mild cognitive impairment. Neurology. 69(7). 631–639. 204 indexed citations

16.

Leverenz, James B., Chang Yu, Thomas J. Montine, et al.. (2007). A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain. 130(5). 1360–1374. 96 indexed citations

17.

Bowen, James D., Richard Kamin, James B. Leverenz, et al.. (2005). Interrater Reliability and Accuracy in Identifying Ischemic Strokes Using Computed Tomography Scans in People with Dementia. Journal of the American Geriatrics Society. 53(10). 1743–1747. 5 indexed citations

18.

Tsuang, Debby W., Gail Li, Steven D. Edland, et al.. (2005). Evaluation of Selection Bias in an Incident-Based Dementia Autopsy Case Series. Alzheimer Disease & Associated Disorders. 19(2). 67–73. 28 indexed citations

19.

Leverenz, James B., et al.. (1999). Effect of Chronic High-Dose Exogenous Cortisol on Hippocampal Neuronal Number in Aged Nonhuman Primates. Journal of Neuroscience. 19(6). 2356–2361. 131 indexed citations

20.

Matsushima, Hiroyuki, Elaine R. Peskind, Judy Clark, et al.. (1997). Protein Changes during Aging and the Effects of Long-Term Cortisol Treatment in Macaque Monkey Lens. Optometry and Vision Science. 74(4). 190–197. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact